- 5- and 10-year recurrence rates are no different for nonsurgical vs surgical management of close anterior margins after breast conserving surgery (BCS) for invasive or in situ breast cancer.
Why this matters
- No current guidelines shed light on whether nonsurgical management of close anterior margins is safe.
- This study suggests that nonsurgical management of close anterior margins is likely to be safe over the long-term when combined with appropriate adjuvant therapy.
- Retrospective cohort of 6922 patients who underwent BCS for breast cancer at 2 UK hospitals from 2000 to 2008.
- Close anterior margins (≤2 mm) after BCS were identified in 277 of these patients, of whom 220 underwent re-excision surgery and 57 were managed nonsurgically.
- Funding: None disclosed.
- Overall, 7% of the nonsurgical group had local recurrence of breast cancer and 5.45% of the surgical group had local recurrence.
- No differences between groups in type of adjuvant therapy after BCS (endocrine therapy, radiotherapy, chemotherapy, and trastuzumab).
- No differences between groups in 5-year recurrence-free survival (RFS: 98.2%; 95% CI, 87.8%-99.7%) and 10-year RFS (92.2%; 95% CI, 80.3%-97.0%; overall HR, 1.24; P=.71).
- Observational, retrospective design.